News
2010 | 2009 | 2008 | 2007 | 2006
London, 19 May 2010
ImmuPharma receives approval for
Initiation of PhaseI/IIA Studies in Cancer
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of IPP-204106, its anti-cancer compound with a novel and promising mechanism of action. The first patients are expected to be dosed within the next few weeks.
London, 19 May 2010
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2009
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2009.
Key Highlights:
Revenue reported of £22 million for the period following the receipt of $30 million from Cephalon, Inc. as a license payment for LupuzorTM in February, 2009
Basic and diluted earnings per share were 10.46p and 9.99p respectively (31 December 2008: 6.23p and 6.07p respectively)
Strong cash position of £22.5 million. Cash balance resulting from LupuzorTM agreement to be used to develop the other promising compounds in the pipeline
Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash received to date - $15m in Q4 2008 and $30m in Q1 2009
Final results of the Phase IIb study of LupuzorTM showed a clinically significant improvement in patient response rate versus placebo
Received IND approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients, IPP-204106, our anti-cancer compound with a novel and promising mechanism of action. First patients expected to be dosed within the next few weeks
Received numerous awards during the year, including: 'Breakthrough of the Year 2009' European Mediscience Award, 'Best Technology 2009' AIM Award and 'Best Drug Development Company Europe 2010' New Economy Award.
London, 8 April 2010
Best Drug Development Company in Europe Award
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.
This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.
London, 5 January 2010
Additional Listing and Total Voting Rights
Following the receipt of a notice of exercise of options, application has been made to the London Stock Exchange for the admission of 365,000 new ordinary shares to trading on AIM. The admission of the new ordinary shares will become effective today. The new ordinary shares rank pari passu with the existing ordinary shares of the Company.
London, 5 January 2010
ING take 4% stake in ImmuPharma plc
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce that ING, Belgium (ING) has taken a 4% stake in the company with the exercise of warrants issued in December 2006. These warrants were exercised on 24 December 2009.
